Melanoma Clinical Trials
The Vermont Cancer Center has many trials specifically focused on skin cancer research.
|Purpose: The purpose of this study is to compare the effects, good and/or bad, of ipilimumab with interferon alfa-2b on you and your melanoma to find out which is better. In this study, you will get either ipilimumab or the interferon alfa-2b. You will not get both. We plan to determine whether ipilimumab stops or delays your cancer from returning in comparison to interferon alfa-2b.|
|ClinicalTrials.gov Identifier: N/A|
|Primary/Site/Co Investigator: Steven Emmons, MD|
|Contact: Elizabeth Eldridge (802) 656-2178|
|Institution Number: M13-171|
|Protocol Research Type: Cooperative Group|
Study Title: A Phase I/II, Open Label Study of Ad-RTS-hIL-12, an Adenovirus Vector Engineered to Express hIL-12, in Combination with an Oral Activator Ligand, in Subjects with Unresectable Stage III or IV Melanoma.
|Purpose: The purpose of this study is to evaluate the safety and tolerability of intratumoral injections of INXN-2001 at a constant dose in combination with and oral drug INXN-1001 in patients who have unresectable stage III or IV melanoma. Additional this study will be evaluating anti-tumor activity (as evidenced by reduction in the size of melanoma tumors).|
|ClinicalTrials.gov Identifier: NCT01397708|
|Primary/Site/Co Investigator: Claire Verschraegen, MD|
|Contact: Kate Murray (802) 656-9401|
|Institution Number: M13-027|
|Protocol Research Type: Industry Sponsored|
Last modified December 06 2013 11:13 AM